Skip to main content
Premium Trial:

Request an Annual Quote

Cequent Begins Long-Term Tox Study with FAP Drug

Premium

Cequent Pharmaceutials said this week that it has begun a long-term toxicology study of its preclinical treatment for familial adenomatous polyposis, dubbed CEQ508.

The drug, which is based on Cequent's proprietary transkingdom RNAi technology, is poised to enter phase I testing this quarter. The company said the toxicology work, which is being conducted in non-human primates, will lay the groundwork for a phase II study to begin in 2011.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more